Hjem › Kronisk lymfatisk leukæmi
Kronisk lymfatisk leukæmi kliniske forsøg rekrutterer i USA
120 studier for Kronisk lymfatisk leukæmi rekrutterer deltagere på steder over hele USA.
Byer med flest studier
- Boston, MA31 studier
- Columbus, OH28 studier
- Durham, NC27 studier
- Washington, DC22 studier
- Seattle, WA20 studier
- Rochester, MN19 studier
- New York City, NY18 studier
- Houston, TX17 studier
- Baldwin Park, CA16 studier
- Milwaukee, WI15 studier
- Cincinnati, OH14 studier
- Chicago, IL14 studier
- Nashville, TN13 studier
- Jacksonville, FL11 studier
- Philadelphia, PA11 studier
- Atlanta, GA11 studier
- Portland, OR10 studier
- Dallas, TX10 studier
- Salt Lake City, UT10 studier
- Kansas City, MO10 studier
- Pittsburgh, PA10 studier
- San Diego, CA10 studier
- Denver, CO9 studier
- Charlotte, NC9 studier
- Miami, FL9 studier
- St. Louis, MO8 studier
- Los Angeles, CA8 studier
- Omaha, NE8 studier
- Des Moines, IA8 studier
- Winston-Salem, NC8 studier
- Queens, NY8 studier
- Tampa, FL8 studier
- Minneapolis, MN8 studier
- Cleveland, OH8 studier
- Clifton, NJ7 studier
- Mountain View, CA7 studier
- Aurora, CO7 studier
- Cedar Rapids, IA7 studier
- Fort Wayne, IN7 studier
- Detroit, MI7 studier
Efter delstat
- Alabama7 studier
- Arizona15 studier
- Arkansas4 studier
- Californien33 studier
- Colorado17 studier
- Connecticut4 studier
- Delaware4 studier
- District of Columbia4 studier
- Florida34 studier
- Georgia16 studier
- Idaho4 studier
- Illinois17 studier
- Indiana12 studier
- Iowa10 studier
- Kansas6 studier
- Kentucky7 studier
- Louisiana6 studier
- Maine6 studier
- Maryland23 studier
- Massachusetts33 studier
- Michigan12 studier
- Minnesota29 studier
- Mississippi5 studier
- Missouri13 studier
- Montana7 studier
- Nebraska8 studier
- Nevada6 studier
- New Hampshire3 studier
- New Jersey13 studier
- New Mexico3 studier
- New York26 studier
- North Carolina34 studier
- Ohio43 studier
- Oklahoma4 studier
- Oregon16 studier
- Pennsylvania22 studier
- Rhode Island6 studier
- South Carolina5 studier
- South Dakota3 studier
- Tennessee17 studier
- Texas38 studier
- Utah10 studier
- Virginia12 studier
- Washington26 studier
- Wisconsin19 studier
Nyligt opdaterede studier
Officiel studietekst (engelsk)
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
RekruttererObservationsstudie
Alder 18 til 110 · Alle køn · Opdateret 2. okt. 2026 · NCT05724121Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RekruttererFase 1
Op til 75 år · Alle køn · Opdateret 2. okt. 2026 · NCT01853631Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
RekruttererFase 3
Alder 65 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT07321652Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06863402Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 40 til 75 · Alle køn · Opdateret 2. okt. 2026 · NCT05334069A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT07582432Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT03516617A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT06542250Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT04269902A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT05645107A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT06943872Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia
RekruttererFase 2
Alder 75 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07685717A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT05006716A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07277231A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT06846671A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT06697184A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT06973187Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
RekruttererObservationsstudie
Alder 18 til 110 · Alle køn · Opdateret 28. sep. 2026 · NCT00923507Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
RekruttererFase 2
Alder 18 til 85 · Alle køn · Opdateret 24. sep. 2026 · NCT03986034A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT05947851A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT06136559Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT06784167Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT01087333A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RekruttererFase 4
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07218341Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 21. sep. 2026 · NCT07648264Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.